

EFFECT OF A SPECIFIC TETRAPEPTIDE FORMULATED IN A LOTION FOR WOMEN SUFFERING CHRONIC HAIR LOSS (CHL)

V. DUROSIER, MD¹ • G. SYLVAIN, MD² • M. JHIN, MD³ • N. KRYWONIS, MD⁴ • J. LEDDON, MD⁵ L. PARKER, MD⁶ • M. GOLDGEIER, MD⁷ • K. WITFILL, MD⁸ • L. EVANS, MD⁹ • D.R. SPEY, MD¹⁰ D. DAY, MD¹¹ • ANTONELLA TOSTI, MD¹²

DUCRAY LABORATORIES, LAVAUR, France • ² EAGLE'S LANDING LONGEVITY CENTER, STOCKBRIDGE, GA, USA
³ PREMIER DERMATOLOGY, SAN FRANCISCO, CA, USA • ⁴ SKIN CARE COLORADO, DENVER, CO, USA
⁵ BOULDER VALLEY CENTER FOR DERMATOLOGY, LAFAYETTE, CO, USA • ⁶ DERMATOLOGY SPECIALISTS, BENCHWOOD, OH, USA ⁷ CLINTON CROSSING DERMATOLOGY, ROCHESTER, NY, USA • ⁸ BAY DERMATOLOGY, PORT RICHEY, FL, USA • ⁹ DERMATOLOGIST, CHAPPAQUA, NY, USA • ¹⁰ ADVANCED DERMATOLOGY AND SKIN CARE, WEST ORANGE, NJ, USA • ¹¹ DAY DERMATOLOGY & AESTHETICS, NEW YORK, NY, USA • ¹² UNIVERSITY OF MIAMI HOSPITAL, MIAMI, FL, USA.

LEARNING OBJECTIVE

Present an alternative treatment in management of female chronic hair loss.

INTRODUCTION


25% of women from 35 to 45 years old and 45% of women over 40 are experiencing CHL (1). The aim of this study was to investigate the effect of a specific tetrapeptide-based lotion in female CHL.

METHODOLOGY

Ten American dermatologists had conducted a study with women suffering from CHL for longer than 1 year. Patients applied 1ml of the lotion once daily for a 3-month period. Global hair loss severity, hair density were evaluated by physicians and patients at baseline (T0) and week 12 with a 10 points scale. Efficacy, clinical response and tolerance of the product were also evaluated.

RESULTS

47 women with an average age of 52 participated in the study. After 3 months of use, dermatologists and patients confirmed a significant improvement in hair density (4,8 to 5,4; p=0, 0192) (Fig 1). At week 12, dermatologists observed a significant decrease in the general severity of chronic alopecia (5,1 to 4,5; p<0,05). The overall efficiency was considered as "good to excellent" for over 81% of subjects. The cutaneous tolerance of the product for 93% of subjects was very good.



CONCLUSION

This study has shown that the tetrapeptide lotion is effective and well tolerated in the management of female CHL.